Like StudyKIK

closed 9/15/2021 via GlobeNewswire

Syneos Health, acquired StudyKIK

synopsis: Syneos Health, the only fully integrated biopharmaceutical solutions organization, announced the acquisition of StudyKIK, a leading technology-enabled clinical trial recruitment and retention company.
buyer: Syneos Health (SYNH:$4,730.38)
Syneos Health is the only fully integrated biopharmaceutical solutions organization. Their company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. "
target: StudyKIK
StudyKIK is a leading technology-enabled clinical trial recruitment and retention company. StudyKIK supports patient recruitment, patient retention, eConsent Solutions, Telemedicine Video Calling, and study companion mobile applications to expedite clinical trials
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 7/13/2017 via BusinessWire

Genoa Healthcare, acquired Medication Management Systems, Inc.

synopsis: The nation’s leading behavioral health pharmacy and telepsychiatry company, Genoa, a QoL Healthcare Company, announced the acquisition of Medication Management Systems, Inc., a Minneapolis-based provider of comprehensive medication therapy management services and technology for complex high-risk patients.
buyer: Genoa Healthcare
Genoa, a QoL Healthcare Company, has been serving the behavioral health community for more than 15 years. The company provides pharmacy and telepsychiatry services to more than 550,000 individuals annually in 48 states & the District of Columbia, filling more than 12 million prescriptions per year. "
target: Medication Management Systems, Inc.
Medication Management Systems, Inc. provides comprehensive, patient–centered medication management services and technology to improve medication therapy by identifying and resolving patients’ medication therapy problems.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 11/15/2017 via BusinessWire

ConnectiveRx, acquired Careform

synopsis: ConnectiveRx, a leader in helping patients with affordability, access and medication adherence messaging, has acquired Careform, a leader in technology-enabled “hub” services driving patient and provider engagement and support.
buyer: ConnectiveRx
Headquartered in Whippany, New Jersey, ConnectiveRx delivers affordability and adherence messaging solutions through all stages of the patient’s medication journey to help them get and stay on their medications. The company provides these solutions to over 125 biopharmaceutical manufacturers. "
target: Careform
Based in Pittsburgh, Pennsylvania, Careform was founded in 2012 to simplify access to specialty pharmaceuticals through technology-enabled patient support services. BrandHub delivers inventory management, EHR integration and therapy cycle management to identify and remove barriers to patient access.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 11/24/2020 via BusinessWire

UpHealth Inc. will be merged with GigCapital, Inc.,

synopsis: GigCapital2, a Technology, Media and Telecom (TMT) Private-to-Public Equity (PPE)™ corporation, announced that it has entered into a business combination agreement with UpHealth, one of the largest national and international digital healthcare providers.
buyer: GigCapital, Inc. (:KLR.ASE:$0.00)
GigCapital is a Private-to-Public Equity technology, media, and telecommunications (TMT) focused investment group. The group deploys a unique Mentor-Investors methodology to partner with exceptional TMT companies, managed by dedicated and experienced entrepreneurs. "
target: UpHealth Inc.
UpHealth is a global comprehensive digital health technology and tech-enabled services platform that empowers providers, health systems and payors globally to manage care for people with complex medical, behavioral and social needs, while dramatically improving access to primary care.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 9/25/2017 via BusinessWire

Konica Minolta, Inc., will acquire Invicro, LLC

synopsis: Konica Minolta, Inc. and Boston-based Invicro LLC announced that they have concluded an agreement whereby Konica Minolta will acquire Invicro, a leading provider of imaging services and software for research and drug development.
buyer: Konica Minolta, Inc. (TSE:4902:$8,793.96)
Konica Minolta, Inc. is a Japanese technology company headquartered in Tokyo. The company manufactures business and industrial imaging products, including copiers, laser printers, multi-functional peripherals (MFPs) and digital print systems for the production printing market. "
target: Invicro, LLC
Invicro is a leading provider of imaging services and software for research and drug development. Headquartered in Boston, Massachusetts, Invicro LLC was founded in 2008 with the mission of improving the role and function of imaging in drug discovery and development across all therapeutic areas.
price ($mm)
rev ($mm)
$106
EBITDA ($mm)
$17
EV / rev
0.0x
EV / EBITDA
0.0x
closed 8/11/2021 via PR Newswire

Sharecare, Inc., acquired CareLinx

synopsis: Sharecare, the digital health company that helps people manage all their health in one place, has closed its acquisition of CareLinx, the nation's leading digital on-demand platform of tech-enabled care providers.
buyer: Sharecare, Inc. (NasdaqGS:SHCR:$331.76)
Sharecare is the digital health company that helps people manage all their health in one place. The Sharecare platform provides each person with a comprehensive and personalized health profile where they can dynamically and easily connect to the information. "
target parent: The Generali Group
target: CareLinx
CareLinx is a leading nationwide, tech-enabled caregiver marketplace improving access to affordable, quality home care for families, large health systems, and insurance companies. CareLinx caregivers leverage proprietary digital care plans to better assist the elderly and disabled.
price ($mm)
$65
rev ($mm)
$5
EBITDA ($mm)
EV / rev
13.0x
EV / EBITDA
closed 10/22/2020 via BusinessWire

Transcarent merged with BridgeHealth,

synopsis: Transcarent, a consumer digital health company, has merged with BridgeHealth, the industry-leading provider of surgical advocacy and centers of excellence programs for large, self-insured organizations. BridgeHealth will introduce new high-touch, high-tech navigation services and solutions built using the Transcarent technology stack.
buyer: BridgeHealth
BridgeHealth is a provider of value-based healthcare services that guide members to surgical Centers of Excellence nationwide. Its bundled rates allow self-insured group health plans to improve the quality and outcomes of surgery while reducing costs from 30% to 50% on average per procedure. "
target: Transcarent
Transcarent is a consumer digital health company that uses a combination of software, technology, and data science to empower consumers with information and access, leading to better outcomes and more cost-effective decisions.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 8/5/2020 via GlobeNewswire

Livongo will be merged with TelaDoc, Inc.,

synopsis: Teladoc Health, the global leader in virtual care, and Livongo, the leading Applied Health Signals company, have entered into a definitive merger agreement. The combination of Teladoc Health and Livongo will create a global leader in consumer centered virtual care. The combined company will operate under the Teladoc Health brand.
buyer: TelaDoc, Inc. (TDOC:$716.29)
Teladoc Health is recognized as the world leader in virtual care. They deliver millions of medical visits across 175 countries annually through the Teladoc Health Medical Group, enabling millions of patient and provider touchpoints for hospitals, health systems, and physician practices globally. "
target: Livongo (LVGO:$257.96)
Livongo empowers people with chronic conditions to live better and healthier lives. Using its AI+AI engine, Livongo aggregates and interprets health data and information to create actionable, personalized, and timely health signals delivered to Livongo Members exactly when and where they need them.
price ($mm)[EV]
$16,988 [$16,567]
rev ($mm)
$258
EBITDA ($mm)
EV / rev
70.8x
EV / EBITDA
announced 7/21/2020 via BNC Analysis

PharmEasy, will acquire Medlife International Private Limited

synopsis: PharmEasy, an online pharmacy startup based in India, will acquire Medlife. Headquartered in Bengaluru, India, Medlife provides medicines, health products, doctor consultations, and tests on its website and app. The acquisition will help PharmEasy secure its position as a market leader in India's online healthcare sector.
buyer: PharmEasy
PharmEasy is India’s leading and most trusted online healthcare aggregator. The company helps patients connect with local pharmacy stores and diagnostic centers to fulfill their medical needs. PharmEasy aims to improve the entire supply chain in the pharma sector by digitizing the entire process. "
target: Medlife International Private Limited
Medlife is India’s largest e-health platform has been focusing on delivering affordable healthcare at doorsteps to make it accessible to all. Medlife offers a range of services, including medicine home delivery, home lab tests, and online doctor consultations through its website and app.
price ($mm)
$235
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 5/18/2009 via BusinessWire

United BioSource Corporation, acquired Healthcare Project Management

synopsis: United BioSource Corporation has announced the acquisition of HPM (Geneva) SA, a Geneva, Switzerland-based provider of drug safety and pharmacovigilance services, further extending UBC’s reach into the European market.
buyer parent: Oak Investment Partners
buyer: United BioSource Corporation
United BioSource Corporation accelerates the generation, analysis and communication of real world evidence by integrating scientific and operational expertise with innovative technology solutions to support global development and commercialization of medical products for life science companies. "
target: Healthcare Project Management
Healthcare Project Management (HPM) is a contract research organization founded in 1997 to provide clinical research services to industry as well as academia. Our core services are drug safety, medical writing and scientific consultancy.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 11/14/2008 via BusinessWire

ICON Plc, acquired Prevalere Life Sciences, Inc.

synopsis: ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, announced that is has acquired Prevalere Life Sciences Inc., a wholly owned subsidiary of ORS Labs Inc.
buyer: ICON Plc (ICLR:$1,541.91)
ICON Clinical Research is a full service clinical research organization providing a comprehensive range of clinical services in Phase I-IV clinical trials to the pharmaceutical, biotechnology and device industries. "
target parent: Oneida Research Services, Inc.
target: Prevalere Life Sciences, Inc.
Prevalere Life Sciences, Inc. is a contract research organization providing consulting and GLP/cGMP compliant analytical testing services to meet the research and development challenges of the pharmaceutical and biotechnology industries.
price ($mm)
$38
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 4/27/2021 via BNC Analysis

TeleMed2U, acquired Medzino United States

synopsis: Medzino, an Austin-based startup specializing in telemedicine and mail order pharmacy, announced that their US brand will be acquired by TeleMed2U, a leading telemedicine company operating out of Austin, Texas and Roseville, California. Medzino is a digital health brand offering online diagnosis, prescriptions by U.S. certified physicians.
buyer parent: Kura MD
buyer: TeleMed2U
Telemed2U is a multi-specialty technology-enabled services company that supplies its clients with real-time access to physician specialists through the use of secure state-of-the-art, audio-visual technology. "
target: Medzino United States
Medzino is an Austin-based digital health brand offering online diagnosis, prescriptions by U.S. certified physicians, and home delivery of medication across 38 US states. Following a short two-minute online consultation, patients are able to request treatment for a range of primary care issues.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 8/2/2017 via BNC Analysis

Cannabis Sativa, Inc., acquired PrestoDoctor

synopsis: Cannabis Sativa. Inc., a company that develops and promotes natural cannabis products, has acquired a 51% stake in PrestoCorp (a.k.a. PrestoDoctor), an online telemedicine platform providing access to knowledgeable physicians for a safe and confidential way to get a medical marijuana recommendation using secure video conferencing technology.
buyer: Cannabis Sativa, Inc. (OTCPK:CBDS:$0.03)
Cannabis Sativa, Inc. develops and promotes natural cannabis products. The Company is engaged in the research, development and licensing of natural cannabis products, including cannabis formulas, edibles, topicals, strains, recipes and delivery systems. "
target: PrestoDoctor
PrestoDoctor is an online telemedicine platform providing access to knowledgeable physicians for a safe and confidential way to get a medical marijuana recommendation using secure video conferencing technology. Appointments are 10-15 minutes long, and can be scheduled and completed in the same day.
price ($mm)
$2.39*
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 11/19/2021 via BNC Analysis

Flipkart, will acquire SastaSundar.com

synopsis: Flipkart, an Indian e-commerce company, will acquire majority stake in SastaSundar.com, an online pharmacy in India. SastaSundar makes high quality medicines and healthcare products more accessible and convenient. They offer products for pain relief, diabetes, oral & dental care, fevers, coughs, headaches, blood pressure, and more.
buyer parent: Walmart
buyer: Flipkart
The Flipkart Group is one of India’s largest e-commerce marketplace and includes group companies Flipkart, Myntra, Jabong, and PhonePe. Flipkart has enabled millions to be a part of India's e-commerce revolution, offering over 150 million products across 80+ categories. "
target: SastaSundar.com
SastaSundar.com is an online pharmacy in India. SastaSundar makes high quality medicines and healthcare products more accessible and convenient. They offer products for pain relief, diabetes, oral & dental care, fevers, coughs, headaches, blood pressure, and more.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 6/27/2019 via BNC Analysis

Farmaciasdirect, acquired Mi Otra Farmacia

synopsis: Farmaciasdirect has purchased the online pharmacy Mi Otra Farmacia (Miotrafarmacia.com) and its Portuguese subsidiary Minhaoutrafarmacia.com. Mi Otra Farmacia is an online pharmacy headquartered in Seville, Spain. Mi Otra Farmacia provides the best deals online for leading brands in the market, such as Eucerin and Avene.
buyer: Farmaciasdirect
Farmaciasdirect is an online pharmacy in Spain. Farmaciasdirect was founded in 2014 by Antonio Campos, a pharmacist who comes from a family with a long pharmaceutical tradition, becoming a portal for the sale of parapharmacy and pharmacy products. "
target: Mi Otra Farmacia
Mi Otra Farmacia is an online pharmacy headquartered in Seville, Spain. Mi Otra Farmacia provides the best deals online for leading brands in the market, such as Somatoline, Avene, Isdin, Mustela, Eucerin, Elancyl, and more.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 5/8/2019 via BNC Analysis

Medlife International Private Limited, acquired Myra

synopsis: Medlife, an award-winning healthcare app in India, has acquired Myra Medicines, an online pharmacy app in India. Myra's mobile app offers fast online access to high quality and cost effective medicines with doorstep delivery. Myra offers over 22,000 products to consumers in select areas of Bangalore and Mumbai.
buyer: Medlife International Private Limited
Medlife is an award-winning healthcare app in India. The Medlife mobile app allows users to easily order over-the-counter and prescription products from the convenience of their home. Medlife also offers online consultation services and their Medlife Essentials brand of pharmaceuticals. "
target: Myra
Myra is an online pharmacy app in India. Myra's mobile app offers fast online access to high quality and cost effective medicines with doorstep delivery. Myra offers over 22,000 products to consumers in select areas of Bangalore and Mumbai.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 5/24/2018 via BNC Analysis

DocMorris N.V., purchased Online Operations from Apo-Rot

synopsis: DocMorris, a dutch online pharmacy, has acquired Apo-Rot's online operations. Apo-Rot is a Pharmacy chain in Germany that provides low-cost pharmaceutical products. Apo-Rot offers a wide range of pharmaceuticals, cosmetics, medical devices, homeopathy products, and pet supplies.
buyer parent: Zur Rose Group AG
buyer: DocMorris N.V.
Founded in 2000, DocMorris is a dutch online pharmacy. DocMorris serves over 4 million customers through phone, e-mail, web, online video-chat, and their mobile app. They offer a variety of pharmaceuticals for allergies, fevers, diabetes, colds, digestion, and more. "
seller: Apo-Rot
Apo-Rot is a Pharmacy chain in Germany that provides low-cost pharmaceutical products and quality service. Their over-the-counter products are 55% cheaper compared to other pharmacies. Apo-Rot offers a wide range of pharmaceuticals, cosmetics, medical devices, homeopathy products, and pet supplies.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 7/4/2016 via Company Press Release

Pharmacy2U Ltd merged with ChemistDirect,

synopsis: Pharmacy2U merged with ChemistDirect.co.uk. Pharmacy2U is an online pharmacy in the UK and is now the largest NHS contracted pharmacy. Their NHS Repeat Prescription Service takes care of everything to get repeat prescriptions delivered for free to their client's door.
buyer: ChemistDirect
ChemistDirect.co.uk is the UK's number 1 online retailer* of pharmacy medications, specialist skincare products, everyday essential toiletries, vitamins, supplements and they even stock a dedicated range of products to keep pets happy and healthy. "
target: Pharmacy2U Ltd
Established in 1999, Pharmacy2U founded online pharmacy in the UK and are now the largest NHS contracted pharmacy*. Their NHS Repeat Prescription Service takes care of everything to get repeat prescriptions delivered for free to their client's door.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 4/5/2006 via PR Newswire

Ventiv Health, acquired Synergos, Inc.

synopsis: inVentiv Health, Inc. announced the completion of its acquisitions of Synergos, Inc., a focused clinical services provider, and Jeffrey Simbrow Associates Inc., Canada's leading healthcare marketing and communications agency. Both acquisitions were announced by inVentiv on March 13.
buyer: Ventiv Health
inVentiv Health, Inc. is the leading provider of commercialization and complementary services to the global pharmaceutical, life sciences and biotechnology industries. inVentiv delivers its customized clinical, sales, marketing and communications solutions. "
target: Synergos, Inc.
Synergos, Inc. is a functional service provider specializing in clinical trials management services, particularly project management and monitoring as well as investigator and patient recruitment. Synergos also provides regulatory affairs and quality compliance services.
price ($mm)
$5.75
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 9/15/2021 via GlobeNewswire

Syneos Health, acquired StudyKIK

synopsis: Syneos Health, the only fully integrated biopharmaceutical solutions organization, announced the acquisition of StudyKIK, a leading technology-enabled clinical trial recruitment and retention company.
buyer: Syneos Health (SYNH:$4,730.38)
Syneos Health is the only fully integrated biopharmaceutical solutions organization. Their company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. "
target: StudyKIK
StudyKIK is a leading technology-enabled clinical trial recruitment and retention company. StudyKIK supports patient recruitment, patient retention, eConsent Solutions, Telemedicine Video Calling, and study companion mobile applications to expedite clinical trials
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 10/6/2021 via GlobeNewswire

Syneos Health, acquired RxDataScience

synopsis: Syneos Health, the only fully integrated biopharmaceutical solutions organization, announced the acquisition of RxDataScience, a leading healthcare-focused data analytics, data management and artificial intelligence (AI) company.
buyer: Syneos Health (SYNH:$4,730.38)
Syneos Health is the only fully integrated biopharmaceutical solutions organization. Their company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. "
target: RxDataScience
RxDataScience builds AI and advanced analytics solutions to address and answer the challenges with healthcare information management and analysis. Their vision is to create a large suite of apps solving specific business problems across the entire pharmaceutical and healthcare value chain.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 9/15/2021 via GlobeNewswire

Syneos Health, acquired StudyKIK

synopsis: Syneos Health, the only fully integrated biopharmaceutical solutions organization, announced the acquisition of StudyKIK, a leading technology-enabled clinical trial recruitment and retention company.
buyer: Syneos Health (SYNH:$4,730.38)
Syneos Health is the only fully integrated biopharmaceutical solutions organization. Their company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. "
target: StudyKIK
StudyKIK is a leading technology-enabled clinical trial recruitment and retention company. StudyKIK supports patient recruitment, patient retention, eConsent Solutions, Telemedicine Video Calling, and study companion mobile applications to expedite clinical trials
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 5/10/2017 via BNC Analysis

inVentiv Health, Inc. will be merged with INC Research, Inc.,

synopsis: INC Research Holdings, Inc., a leading global Phase I-IV Contract Research Organization ("CRO"), and inVentiv Health, Inc., a leading, global CRO and Contract Commercial Organization will merge. INC Research shareholders will own approximately 53 percent and inVentiv shareholders will own approximately 47 percent of the merged entity.
buyer: INC Research, Inc. (SYNH:$4,730.38)
INC Research is a leading global contract research organization ("CRO") providing the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. "
target parent: Thomas H. Lee Partners, L.P.
target: inVentiv Health, Inc.
inVentiv Health is a global professional services organization designed to help the biopharmaceutical industry accelerate the delivery of much-needed therapies to market. Their Clinical Research Organization (CRO) and Contract Commercial Organization (CCO) offer a differentiated suite of services.
price ($mm)[EV]
$2,453 [$4,552]
rev ($mm)
$2,156
EBITDA ($mm)
$306
EV / rev
2.1x
EV / EBITDA
14.9x
announced 6/1/2009 via Reuters

INC Research, Inc., will purchase Late Stage Research Unit from MDS, Inc.

synopsis: MDS Inc has announced that it planns to narrow its contract research focus by selling its late stage operations and central laboratory divisions to Contract Research Organization INC Research, Inc.
buyer: INC Research, Inc. (SYNH:$4,730.38)
INC Research is a therapeutically focused contract research organization with an unrivaled reputation for conducting Phase I- Phase IV clinical development programs of the highest integrity. "
seller: MDS, Inc. (MDZ:$231.00)
MDS Inc. is a global life sciences company that provides market-leading products and services that are used by its customers for the development of drugs, and the diagnosis and treatment of disease. The Company has more than 5,000 employees in 29 countries and net revenues of more than US$1.2 bil.
price ($mm)
$45
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 9/25/2017 via BusinessWire

Konica Minolta, Inc., will acquire Invicro, LLC

synopsis: Konica Minolta, Inc. and Boston-based Invicro LLC announced that they have concluded an agreement whereby Konica Minolta will acquire Invicro, a leading provider of imaging services and software for research and drug development.
buyer: Konica Minolta, Inc. (TSE:4902:$8,793.96)
Konica Minolta, Inc. is a Japanese technology company headquartered in Tokyo. The company manufactures business and industrial imaging products, including copiers, laser printers, multi-functional peripherals (MFPs) and digital print systems for the production printing market. "
target: Invicro, LLC
Invicro is a leading provider of imaging services and software for research and drug development. Headquartered in Boston, Massachusetts, Invicro LLC was founded in 2008 with the mission of improving the role and function of imaging in drug discovery and development across all therapeutic areas.
price ($mm)
rev ($mm)
$106
EBITDA ($mm)
$17
EV / rev
0.0x
EV / EBITDA
0.0x
closed 8/16/2017 via BusinessWire

Evotec BioSystems GmbH, acquired Aptuit, Inc.

synopsis: Evotec announced that it has successfully completed the acquisition of Aptuit, a partner research organisation for integrated outsourced drug discovery and development solutions. This acquisition adds considerable business opportunities to further accelerate Evotec's long-term strategy to be the industry partner of choice for external innovation.
buyer: Evotec BioSystems GmbH (XTRA:EVT:$226.46)
Founded in Hamburg Germany, Evotec BioSystems GmbH is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. "
target parent: Welsh, Carson, Anderson & Stowe
target: Aptuit, Inc.
Aptuit, Inc. (formerly Global Pharmaceutical Development, Inc.) is an emerging company focused on streamlining and supporting the drug development process for biotechnology and pharmaceutical innovators.
price ($mm)
$300
rev ($mm)
$93
EBITDA ($mm)
$12
EV / rev
3.2x
EV / EBITDA
25.8x
announced 6/20/2017 via Company Press Release

Pamplona Capital Management LLP, will acquire PAREXEL International Corporation

synopsis: Pamplona Capital Management, LLP has entered into a definitive agreement to acquire all of the outstanding shares of PAREXEL International Corporation, a leading global biopharmaceutical services provider. PAREXEL provides a broad range of expertise-based clinical research, consulting, medical communications, and technology solutions and services.
buyer: Pamplona Capital Management LLP
Pamplona Capital Management is a London, New York, and Boston-based specialist investment manager established in 2005 that provides an alternative investment platform across private equity, fund of hedge funds, and single-manager hedge fund investments. "
target: PAREXEL International Corporation (PRXL:$1,939.36)
PAREXEL International Corporation is a leading global biopharmaceutical services company, providing a broad range of clinical research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology and medical device industries.
price ($mm)[EV]
$4,508 [$4,923]
rev ($mm)
$2,097
EBITDA ($mm)
$343
EV / rev
2.4x
EV / EBITDA
14.6x
announced 5/10/2017 via BNC Analysis

inVentiv Health, Inc. will be merged with INC Research, Inc.,

synopsis: INC Research Holdings, Inc., a leading global Phase I-IV Contract Research Organization ("CRO"), and inVentiv Health, Inc., a leading, global CRO and Contract Commercial Organization will merge. INC Research shareholders will own approximately 53 percent and inVentiv shareholders will own approximately 47 percent of the merged entity.
buyer: INC Research, Inc. (SYNH:$4,730.38)
INC Research is a leading global contract research organization ("CRO") providing the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. "
target parent: Thomas H. Lee Partners, L.P.
target: inVentiv Health, Inc.
inVentiv Health is a global professional services organization designed to help the biopharmaceutical industry accelerate the delivery of much-needed therapies to market. Their Clinical Research Organization (CRO) and Contract Commercial Organization (CCO) offer a differentiated suite of services.
price ($mm)[EV]
$2,453 [$4,552]
rev ($mm)
$2,156
EBITDA ($mm)
$306
EV / rev
2.1x
EV / EBITDA
14.9x
closed 10/3/2016 via BusinessWire

Quintiles Transnational Corp. merged with IMS Health Incorporated,

synopsis: Quintiles IMS Holdings, Inc. announced that it has successfully completed its merger of equals transaction between IMS Health Holdings, Inc. and Quintiles Transnational Holdings Inc. The merger creates a leading information and tech-enabled global healthcare service provider, and a full suite of end-to-end clinical and commercial offerings.
buyer: IMS Health Incorporated (NYSE:IQV:$10,412.00)
IMS Health is a leading global information and technology services company providing clients in the healthcare industry with end-to-end solutions to measure and improve their performance. They connect configurable SaaS applications to complex healthcare data in the IMS One™ cloud platform. "
target: Quintiles Transnational Corp. (Q:$4,497.17)
Quintiles is the world’s largest provider of biopharmaceutical development services and commercial outsourcing services. They help customers navigate the increasingly complex healthcare environment to improve efficiency and to deliver better healthcare outcomes.
price ($mm)
$8,750
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 11/6/2009 via BusinessWire

PPD, Inc., acquired Excel PharmaStudies Inc.

synopsis: PPD, Inc. announced it has completed its acquisition of Excel PharmaStudies, Inc., one of the largest contract research organizations in China. The acquisition strengthens PPD’s full range of drug development services in the country and positions it to capitalize on the tremendous growth of the outsourcing market in Asia Pacific.
buyer: PPD, Inc.
PPD is a leading global contract research organization (CRO) providing discovery, development and post-approval services as well as compound partnering programs. PPD's clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. "
target: Excel PharmaStudies Inc.
Excel PharmaStudies, Inc. is a full-service provider of clinical research, registration, biometrics, and training and consultation services. Excel is the leading CRO in China and operates 22 offices worldwide, with more than 300 staff members.
price ($mm)
$16
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 7/17/2009 via PR Newswire

Pierrel SpA, purchased US Operations from Encorium Group Inc.

synopsis: Encorium Group, Inc., a full service multinational clinical research organization, announced that is has completed the previously announced sale of the Company's U.S. business to Pierrel Research USA, Inc., a wholly-owned subsidiary of Pierrel SpA, an international contract research organization listed on Milano's Stock Exchange.
buyer: Pierrel SpA (PIELF:$0.00)
Pierrel S.p.A. is a pharmaceutical company specializing in contract research, development and the manufacture of medicines. The Pierrel Group boasts over 50 years of experience in the pharmaceutical sector, and is one of the main Italian manufacturers of local anaesthetics for dental use. "
seller: Encorium Group Inc.
Encorium is a full-service Contract Research Organization providing comprehensive solutions for pharmaceutical, biotechnology, and medical device companies. At Encorium we recognize the challenges that often arise during drug development.
price ($mm)[EV]
$0.08 [$2.58]
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 4/8/2009 via PR Newswire

Next Fuel, Inc., will acquire Clinical Trials of the Americas, Inc.

synopsis: Clinical Trials of America Inc. announced that it has entered into a binding letter of intent to sell shares equal to approximately 75% of its issued and outstanding shares to Next Fuel Inc., a developer of a proprietary "On Demand" Hydrogen Generation System.
buyer: Next Fuel, Inc.
Next Fuel Inc. is a developer of a proprietary "On Demand" Hydrogen Generation System that is used as fuel for Fuel Cells which produce electricity. "
target: Clinical Trials of the Americas, Inc.
Clinical Trials of the Americas, Inc. provides clinical trial investigator services in dedicated sites throughout the Americas. Initially, we intend to introduce our services in Central America.
price ($mm)
$0.29*
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 3/2/2009 via PR Newswire

ASG, Inc., acquired Ockham Development Group, Inc.

synopsis: ASG, Inc. a high-quality functional outsourcing and specialty staffing services group based in Cary, North Carolina - has acquired neighboring Ockham Development Group, Inc., a full-service contract research organization.
buyer: ASG, Inc.
ASG provides high-quality functional outsourcing and specialty staffing services to CROs, pharmaceutical, biotech and medical device companies that require clinical operations, GCP, GLP or GMP auditing, data management, statistical programming, biostatistics and medical writing solutions. "
target: Ockham Development Group, Inc.
Ockham Development Group Inc. is a privately held contract research organization headquartered in Cary, North Carolina.
price ($mm)
rev ($mm)
$12
EBITDA ($mm)
EV / rev
0.0x
EV / EBITDA
closed 4/22/2009 via BusinessWire

PPD, Inc., acquired AbCRO, Inc.

synopsis: PPD, Inc. announced that it has completed the acquisition of AbC.R.O., Inc., a Bulgarian contract research organization. The acquisition strengthens PPD’s ability to provide a broad range of clinical trial management and monitoring, patient recruitment, site identification and regulatory affairs services to its growing client base in the Balkans.
buyer: PPD, Inc.
PPD is a leading global contract research organization (CRO) providing discovery, development and post-approval services as well as compound partnering programs. PPD's clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. "
target: AbCRO, Inc.
AbCRO provides a full range of Phase II-IV clinical services, including clinical trial management and monitoring, patient recruitment, site identification and regulatory affairs.
price ($mm)
$36
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 3/20/2009 via PR Newswire

PharmaNet Development Group, Inc. merged with JLL Partners,

synopsis: JLL Partners, a leading private equity investment fund, and PharmaNet Development Group, Inc., a leading provider of clinical development services, announced the successful completion of the tender offer by JLL PharmaNet Holdings, LLC.
buyer: JLL Partners
Founded in 1988, JLL Partners is among the leading private equity investment firms in the country. Since inception, we have managed a series of private equity funds aggregating approximately $4 billion in committed capital. "
target: PharmaNet Development Group, Inc.
PharmaNet Development Group, Inc. is a leader in outsourced clinical development that offers clinical-development solutions including early and late stage consulting services, Phase I clinical studies and bioanalytical analyses, and Phase II, III and IV clinical development programs.
price ($mm)[EV]
$101 [$186]
rev ($mm)
$451
EBITDA ($mm)
$26
EV / rev
0.4x
EV / EBITDA
7.1x
closed 1/27/2009 via BusinessWire

Altarum Institute, acquired KAI Research, Inc.

synopsis: Altarum Institute, a non-profit health systems research and consulting organization, has purchased Rockville, Maryland-based KAI Research, Inc. (KAI). KAI provides innovative, cost-effective and practical support to the pharmaceutical and biotech industry, academic institutions and the National Institutes of Health.
buyer: Altarum Institute
Altarum Institute is a nonprofit health systems research and consulting organization serving government and private-sector clients. "
target: KAI Research, Inc.
KAI Research provides innovative, cost-effective and practical support to the pharmaceutical and biotech industries. KAI currently supports pharmaco-vigilance activities for over 90 marketed drugs and is providing safety surveillance for dozens of ongoing clinical trials.
price ($mm)
$7.55
rev ($mm)
$10
EBITDA ($mm)
EV / rev
0.8x
EV / EBITDA
closed 3/13/2009 via BNC Analysis

Premier Research Group, acquired Pivotal Research Centers, LLC

synopsis: PHC, Inc. d/b/a Pioneer Behavioral Health, a leading provider of inpatient and outpatient behavioral health services, announced Premier Research Arizona, LLC, a unit of Premier Research Group PLC, has signed a purchase agreement to acquire the assets of PHC's Pivotal Research Centers.
buyer: Premier Research Group
Premier Research is a leading solutions-driven CRO committed to therapeutic focus and operational expertise to deliver clinical trial services of the highest quality for biopharmaceutical and medical device companies. "
target parent: Pioneer Behavioral Health
target: Pivotal Research Centers, LLC
Pivotal Research Centers, LLC provides clinical drug testing. It performs all phases of clinical research for Phase I to Phase IV drugs under development through two research sites. Pivotal was founded by Louis C. Kirby in 1993 and is based in Phoenix, Arizona.
price ($mm)
$3.00
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 10/30/2007 via Company Press Release

Chiltern International Inc., acquired Clinical Trial Management Services, Inc.

synopsis: Chiltern, a leading global clinical research organization (CRO), announced the acquisition of Clinical Trial Management Services, Inc. (CTMS) a Bristol, Tennessee based CRO offering high quality services throughout the United States.
buyer: Chiltern International Inc.
Chiltern is a global CRO with experience running and staffing international Phase I to Phase IV clinical trials. Chiltern’s services include: Early Phase, Global Clinical Development, Late Phase, Biometrics, Medical and Regulatory Affairs and Resourcing Solutions. "
target: Clinical Trial Management Services, Inc.
Clinical Trial Management Services, Inc. provides clinical research services such as clinical trial management and monitoring services, such as project management, investigative site management and monitoring services.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 12/14/2009 via BusinessWire

NexMed, Inc., acquired Bio-Quant, Inc.

synopsis: NexMed, Inc., a developer of products based on the NexACT® technology, announced the closing of its acquisition of Bio-Quant, Inc., a privately-held leading research organization for in vitro and in vivo contract drug discovery and pre-clinical development services, headquartered in San Diego, CA.
buyer: NexMed, Inc. (NEXM:$0.00)
NexMed is an innovative drug developer that is leveraging its proprietary NexACT® drug delivery technology to produce a host of new medical treatments. NexMed’s drugs address a variety of health conditions, such as nail fungus, sexual disorders and more. "
target: Bio-Quant, Inc.
Founded in 1999, Bio-Quant is the largest specialty CRO based in San Diego and is one of the industry's most experienced CROs for in vitro and in vivo pharmacology services and research models specializing in oncology, inflammation, immunology, and metabolic diseases, including diabetes.
price ($mm)[EV]
$13 [$13]
rev ($mm)
$5
EBITDA ($mm)
EV / rev
2.5x
EV / EBITDA
announced 10/28/2009 via PR Newswire

Alpha Analytical, will acquire Boston Analytical

synopsis: Alpha Analytical is announcing the completion of the acquisition of Boston Analytical, Inc. Established in 1987, Boston Analytical is a registered, cGMP compliant contract testing laboratory providing quality analytical and microbiological testing services to the pharmaceutical, biotech, device, cosmetic and nutritional product industries.
buyer: Alpha Analytical
Alpha Analytical, Inc. provides full-service environmental laboratory solutions for the most demanding industrial and commercial applications in the U.S. and abroad. Alpha Analytical is the largest environmental laboratory in New England and among the top 18 laboratories in the country. "
target: Boston Analytical
Boston Analytical is committed to providing quality Analytical and Microbiological testing services to pharmaceutical companies worldwide in support of their Product Development, Release and Stability Testing objectives.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 10/12/2009 via Company Press Release

J O Hambro Capital Management Limited, acquired Celsis International

synopsis: Chicago-based Celsis International, a leading global life sciences company, announces that it has been acquired by UK-based private equity firm J O Hambro and will de-list from the London Stock Exchange (LSE) and operate as a privately held company.
buyer: J O Hambro Capital Management Limited
J O Hambro Capital Management, the London-based boutique investment firm, offers an alternative to the large traditional fund management firms that have dominated the market for many years. "
target: Celsis International
Celsis International plc is a leading international provider of innovative life science products and laboratory services to the pharmaceutical and consumer products industries through our three divisions: Rapid Detection, Analytical Services and In Vitro Technologies.
price ($mm)[EV]
$55 [$52]*
rev ($mm)
$42
EBITDA ($mm)
$12
EV / rev
1.9x
EV / EBITDA
6.3x
closed 7/16/2009 via PR Newswire

Water Street Healthcare Partners, acquired AAIPharma Services

synopsis: Water Street Healthcare Partners, a leading private equity firm focused exclusively on the health care industry, announced that it has acquired the Pharmaceutical Development division from AAIPharma Inc.
buyer: Water Street Healthcare Partners
Water Street Healthcare Partners is a leading private equity firm focused exclusively on health care. With more than $1 billion of capital under management, Water Street is one of the most active investors in the health care industry. "
target parent: AAIPharma Inc.
target: AAIPharma Services
AAIPharma Services serves more than 300 large pharmaceutical and biotechnology companies. Its team of 450 scientists and professionals specialize in services that encompass the entire process of pharmaceutical drug development from discovery through commercialization.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 6/1/2009 via Reuters

INC Research, Inc., will purchase Late Stage Research Unit from MDS, Inc.

synopsis: MDS Inc has announced that it planns to narrow its contract research focus by selling its late stage operations and central laboratory divisions to Contract Research Organization INC Research, Inc.
buyer: INC Research, Inc. (SYNH:$4,730.38)
INC Research is a therapeutically focused contract research organization with an unrivaled reputation for conducting Phase I- Phase IV clinical development programs of the highest integrity. "
seller: MDS, Inc. (MDZ:$231.00)
MDS Inc. is a global life sciences company that provides market-leading products and services that are used by its customers for the development of drugs, and the diagnosis and treatment of disease. The Company has more than 5,000 employees in 29 countries and net revenues of more than US$1.2 bil.
price ($mm)
$45
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 4/17/2009 via PR Newswire

ChemRar High-Tech Center, acquired Prudentas, LLC

synopsis: ChemDiv, a global chemistry-driven contract research organization, announced that its ChemRar High Tech Center has acquired Prudentas LLC, one of the leading CRO companies conducting high quality Phase I - Phase IV studies in Eastern Europe.
buyer parent: ChemDiv, Inc.
buyer: ChemRar High-Tech Center
The ChemRar High-Tech Center is a unique pharma and biotechnology complex founded by innovative life science organizations in Russia. ChemRar's component companies are engaged in discovering, developing and commercializing novel drugs for partners in Russia and worldwide. "
target: Prudentas, LLC
Prudentas is a Russian Clinical Contract Research Organization founded by and consisting of highly qualified clinical research professionals with extensive experience of working previously together as a team.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA

Like StudyKIK


read more

StudyKIK

Medication Management Systems, Inc.

Careform

UpHealth Inc.

Invicro, LLC

CareLinx

Transcarent

Livongo

Medlife International Private Limited

Healthcare Project Management

Prevalere Life Sciences, Inc.

Medzino United States

PrestoDoctor

SastaSundar.com

Mi Otra Farmacia

Myra

Apo-Rot

Pharmacy2U Ltd

Synergos, Inc.

read more

StudyKIK

read more

RxDataScience

StudyKIK

inVentiv Health, Inc.

MDS, Inc.

read more

Invicro, LLC

Aptuit, Inc.

PAREXEL International Corporation

inVentiv Health, Inc.

Quintiles Transnational Corp.

Excel PharmaStudies Inc.

Encorium Group Inc.

Clinical Trials of the Americas, Inc.

Ockham Development Group, Inc.

AbCRO, Inc.

PharmaNet Development Group, Inc.

KAI Research, Inc.

Pivotal Research Centers, LLC

Clinical Trial Management Services, Inc.

Bio-Quant, Inc.

Boston Analytical

Celsis International

AAIPharma Services

MDS, Inc.

Prudentas, LLC

Geography
Matching Companies
Ticker: RVNC
 
 
 
 
 
 
 
 
Revance Therapeutics, Inc.
Revance Therapeutics, Inc.
Revance Therapeutics, Inc. is a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection.
year
2020
rev ($mm)
$0.19
EBITDA ($mm)
($185.77)
EBIT ($mm)
($188.79)
Net Income ($mm)
Employees
193
  • drill down
  • watch
Ticker:
 
 
 
 
 
 
 
 
Novartis AG
Novartis AG
Novartis is a Swiss multinational pharmaceutical company based in Basel, Switzerland. It is one of the largest pharmaceutical companies by both market capitalization and sales. Their focus is on cancer, immunology, dermatology, cardiovascular, renal and more.
year
2019
rev ($mm)
$48,677.00
EBITDA ($mm)
$15,532.00
EBIT ($mm)
$11,351.00
Net Income ($mm)
$11,732.00
Employees
103914
  • drill down
  • watch
Ticker: DB:MRK
 
 
 
 
 
 
 
 
Merck KGaA
Merck KGaA
Merck KGaA is a German multinational pharmaceutical, chemical and life sciences company. Merck is the world's oldest operating chemical and pharmaceutical company. The group develops a variety of prescription medicines and specialty chemicals.
year
2019
rev ($mm)
$17,234.26
EBITDA ($mm)
$4,219.33
EBIT ($mm)
$2,268.49
Net Income ($mm)
$3,866.88
Employees
53051
  • drill down
  • watch
Ticker: LSE:BTG
 
 
 
 
 
 
 
 
BTG International Ltd.
BTG is focused on developing innovative products in specialist areas of medicine to better serve doctors and patients. Their growing portfolio of Interventional Medicine products is designed to advance the treatment of cancer, severe emphysema, severe blood clots, and varicose veins.
year
2016
rev ($mm)
$646.34
EBITDA ($mm)
$150.64
EBIT ($mm)
$89.00
Net Income ($mm)
$28.38
Employees
1370
  • drill down
  • watch
Ticker: OTCPK:PRLX
 
 
 
 
 
 
 
 
Parallax Health Sciences, Inc.
Parallax Health Sciences, Inc. is an innovative biomedical healthcare company delivering consumer-centric products and services in the areas of pharmaceuticals, digital health and remote patient monitoring, behavioral health and point of care diagnostics.
year
2016
rev ($mm)
$18.98
EBITDA ($mm)
($1.31)
EBIT ($mm)
($1.43)
Net Income ($mm)
Employees
34
  • drill down
  • watch
Ticker: BSE:531637
 
 
 
 
 
 
 
 
Sword and Shield Pharma Ltd.
Sword and Shield Pharma Ltd.
Sword & Shield Pharma is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. They offer a portfolio of products including Active Pharmaceutical Ingredients, generics, differentiated formulations and News Chemical Entities.
year
2016
rev ($mm)
EBITDA ($mm)
EBIT ($mm)
Net Income ($mm)
Employees
  • drill down
  • watch
Ticker: BOVESPA:RADL3
 
 
 
 
 
 
 
 
Raia Drogasil S.A.
Raia Drogasil S.A.
Raia Drogasil is a leading company in the Brazilian pharmacy market, with over 2,100 stores in 23 Brazilian states. The company was created in November 2011, after the merger between Raia SA and Drogasil SA.
year
2021
rev ($mm)
$4,215.40
EBITDA ($mm)
$342.28
EBIT ($mm)
$240.54
Net Income ($mm)
$141.59
Employees
47208
  • drill down
  • watch
Ticker: JASDAQ:7688
 
 
 
 
 
 
 
 
Merhalsa
Merhalsa
Merhalsa is a Japanese company engaged in the medicine, nursing, and childcare businesses. Their pharmaceutical division operates 41 pharmacies in Tokyo. Their nursing department provides nursing services to the elderly. Merhalsa also operates 26 nursery schools in Japan.
year
2020
rev ($mm)
$155.14
EBITDA ($mm)
$6.29
EBIT ($mm)
$3.27
Net Income ($mm)
$4.04
Employees
2448
  • drill down
  • watch
Ticker: OTCPK:RXMD
 
 
 
 
 
 
 
 
Progressive Care Inc.
Progressive Care Inc.
Progressive Care is a personalized healthcare services and technology company. Progressive Care, through its subsidiary PharmCo, LLC, provides effective and affordable prescription pharmaceuticals. The company also specalizes in health practice risk management, tele-pharmacy services and more.
year
2012
rev ($mm)
$10.03
EBITDA ($mm)
($0.31)
EBIT ($mm)
($0.57)
Net Income ($mm)
Employees
31
  • drill down
  • watch
Ticker: KRBP
 
 
 
 
 
 
 
 
Kiromic
Kiromic
Kiromic is an immuno-oncology, target discovery and gene editing company. Kiromic is developing safe tumor-specific cancer engineered immunotherapies to face and defeat multiple cancer types. The company is focused on extending the benefits of immunotherapy by leveraging their DIAMOND AI platform.
year
2021
rev ($mm)
EBITDA ($mm)
($21.04)
EBIT ($mm)
($21.30)
Net Income ($mm)
Employees
19
  • drill down
  • watch
Ticker: ENXTPA:ERF
 
 
 
 
 
 
 
 
Eurofins Group
Eurofins Group
Based in Luxembourg, Eurofins is a leading international group of laboratories providing a unique range of analytical testing services to the pharmaceutical, food, environmental and consumer products industries and to governments.
year
2019
rev ($mm)
$5,244.00
EBITDA ($mm)
$922.65
EBIT ($mm)
$524.54
Net Income ($mm)
$224.34
Employees
47427
  • drill down
  • watch
Ticker: CRL
 
 
 
 
 
 
 
 
Charles River Laboratories International Inc.
Charles River Laboratories International Inc.
Charles River has been helping our global partners accelerate drug discovery and development by providing them with tailored research models and preclinical, clinical, support services.
year
2009
rev ($mm)
$1,202.55
EBITDA ($mm)
$282.48
EBIT ($mm)
$188.93
Net Income ($mm)
$114.44
Employees
8000
  • drill down
  • watch
Ticker: TSE:2796
 
 
 
 
 
 
 
 
Pharmarise Holdings Corporation
Pharmarise Holdings Corporation
Pharmarise Holdings Corporation manages dispensing pharmacies in Japan. Its dispensing pharmacies provide patients with dispensing services based on prescriptions drawn up by medical institutions. The company also manages drug stores and convenience stores; and sells cosmetics.
year
2017
rev ($mm)
$467.23
EBITDA ($mm)
$14.81
EBIT ($mm)
$3.64
Net Income ($mm)
Employees
1364
  • drill down
  • watch
Ticker: ABC
 
 
 
 
 
 
 
 
AmerisourceBergen Corporation
AmerisourceBergen Corporation
AmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care. Tens of thousands of healthcare providers, veterinary practices and livestock producers trust them as their partner in the pharmaceutical supply chain.
year
2019
rev ($mm)
$175,151.50
EBITDA ($mm)
$2,276.42
EBIT ($mm)
$1,735.61
Net Income ($mm)
$929.88
Employees
20500
  • drill down
  • watch
Ticker: ADRX
 
 
 
 
 
 
 
 
Andrx Corporation
Andrx Corporation is committed to providing: high quality, cost effective pharmaceuticals to our customers and to patients; sustained profit and revenue growth to our stockholders; and an employee culture that is stimulating and rewarding.
year
2005
rev ($mm)
$1,145.10
EBITDA ($mm)
$132.00
EBIT ($mm)
$95.90
Net Income ($mm)
$65.70
Employees
0
  • drill down
  • watch
Ticker: SYNH
 
 
 
 
 
 
 
 
INC Research, Inc.
INC Research, Inc.
INC Research is a leading global contract research organization ("CRO") providing the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries.
year
2021
rev ($mm)
$4,730.38
EBITDA ($mm)
$633.74
EBIT ($mm)
$407.86
Net Income ($mm)
$235.93
Employees
24310
  • drill down
  • watch
Ticker: ICLR
 
 
 
 
 
 
 
 
ICON Plc
ICON Plc
ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company specialises in the strategic development, management and analysis of programs that support clinical development.
year
2015
rev ($mm)
$1,541.91
EBITDA ($mm)
$289.74
EBIT ($mm)
$234.82
Net Income ($mm)
$192.14
Employees
11200
  • drill down
  • watch
Ticker:
 
 
 
 
 
 
 
 
CMIC Co., Ltd.
CMIC is a leading full-service CRO in Japan offering a wide range of services in clinical trials in Asia to both multi-national and Japanese pharma companies.
year
2019
rev ($mm)
$664.65
EBITDA ($mm)
$76.21
EBIT ($mm)
$43.15
Net Income ($mm)
$23.12
Employees
4962
  • drill down
  • watch
Ticker: PIELF
 
 
 
 
 
 
 
 
Pierrel SpA
Pierrel SpA
Pierrel S.p.A. is a pharmaceutical company specializing in contract research, development and the manufacture of medicines. The Pierrel Group boasts over 50 years of experience in the pharmaceutical sector, and is one of the main Italian manufacturers of local anaesthetics for dental use.
year
2008
rev ($mm)
$64.38
EBITDA ($mm)
($4.23)
EBIT ($mm)
($8.92)
Net Income ($mm)
Employees
504
  • drill down
  • watch
Ticker: ENCO
 
 
 
 
 
 
 
 
Encorium Group Inc.
Encorium is a full-service Contract Research Organization providing comprehensive solutions for pharmaceutical, biotechnology, and medical device companies. At Encorium we recognize the challenges that often arise during drug development.
year
2008
rev ($mm)
$35.91
EBITDA ($mm)
($5.19)
EBIT ($mm)
($6.89)
Net Income ($mm)
Employees
226
  • drill down
  • watch
Ticker: ENXTPA:ERF
 
 
 
 
 
 
 
 
Eurofins Group
Eurofins Group
Based in Luxembourg, Eurofins is a leading international group of laboratories providing a unique range of analytical testing services to the pharmaceutical, food, environmental and consumer products industries and to governments.
year
2019
rev ($mm)
$5,244.00
EBITDA ($mm)
$922.65
EBIT ($mm)
$524.54
Net Income ($mm)
$224.34
Employees
47427
  • drill down
  • watch
Ticker: CRL
 
 
 
 
 
 
 
 
Charles River Laboratories International Inc.
Charles River Laboratories International Inc.
Charles River has been helping our global partners accelerate drug discovery and development by providing them with tailored research models and preclinical, clinical, support services.
year
2009
rev ($mm)
$1,202.55
EBITDA ($mm)
$282.48
EBIT ($mm)
$188.93
Net Income ($mm)
$114.44
Employees
8000
  • drill down
  • watch
Ticker: NEO
 
 
 
 
 
 
 
 
NeoGenomics Laboratories
NeoGenomics Laboratories
NeoGenomics is a leading cancer diagnostic reference laboratory. NeoGenomics offers testing services for oncologists, pathologists, and pharmaceutical centers. Their areas of expertise include cancer cytogenetics, hematologic and solid tumor FISH testing, molecular oncology tests, and more.
year
2020
rev ($mm)
$444.45
EBITDA ($mm)
$23.80
EBIT ($mm)
($11.92)
Net Income ($mm)
$4.17
Employees
1700
  • drill down
  • watch
Ticker: LH
 
 
 
 
 
 
 
 
LabCorp
LabCorp provides leading-edge medical laboratory tests and services through a national network of primary clinical laboratories and specialty testing laboratories. LabCorp processes tests on approximately 470,000 specimens each day, applying advances in medicine and science to laboratory testing.
year
2021
rev ($mm)
$16,388.10
EBITDA ($mm)
$4,886.00
EBIT ($mm)
$4,358.30
Net Income ($mm)
$2,878.70
Employees
68780
  • drill down
  • watch